Market News & Trends
Dauntless Pharmaceuticals Announces Positive Data
Dauntless Pharmaceuticals, Inc. recently announced positive results from its two-part, Phase 1 pharmacokinetic/pharmacodynamic study evaluating DP1038, a novel formulation of octreotide acetate for intranasal administration.…
Feldan Therapeutics & Elasmogen Announce Research Agreement With Amgen
Elasmogen Ltd and Feldan Therapeutics recently announced a research collaboration with Amgen to develop and deliver novel intracellular biologics. The collaboration combines the unique capabilities…
Dalton Pharma Services Signs Development & Manufacturing Agreement
Dalton Pharma Services, a leading pharmaceutical cGMP contract manufacturing company, recently announced the signing of a drug development and manufacturing services agreement with Arch Biopartners,…
Adamas Signs $100-Million Royalty-Backed Note Agreement
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) recenbtly announced that it has entered into a $100-million royalty-backed note agreement with HealthCare Royalty Partners (HCR). Under the…
Adamas Signs $100-Million Royalty-Backed Note Agreement
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) recenbtly announced that it has entered into a $100-million royalty-backed note agreement with HealthCare Royalty Partners (HCR). Under the…
Lupin Announces Opening of New Expansion at its NJ Manufacturing Site
The leadership of Lupin Limited gathered along with state and local leaders, including Rep. Bonnie Watson Coleman (DNJ – 12th District), to celebrate the grand…
Lupin Announces Opening of New Expansion at its NJ Manufacturing Site
The leadership of Lupin Limited gathered along with state and local leaders, including Rep. Bonnie Watson Coleman (DNJ – 12th District), to celebrate the grand…
Sanofi & Regeneron Announce Biologics License Application Resubmission is Accepted for Review
Sanofi and Regeneron Pharmaceuticals, Inc. recently announced that the US FDA has accepted the resubmission of Biologics License Application for Kevzara (sarilumab) as a Class…
Clinical Trial Results Marks a Significant Accomplishment for Medicortex Finland
Medicortex Finland Oy (http://www.medicortex.fi) recently announced it completed analyzing the results from the first clinical trial. Medicortex is working toward the validation of a Traumatic…
enGene, Inc.'s Mucosal Gene Delivery Platform is Successful
enGene Inc. recently announced that data from preclinical studies demonstrated successful expression of programmed death-ligand 1 (PD-L1) protein in the gut showing therapeutic efficacies in…
Daiichi Sankyo Announces Multi-Billion Manufacturing Investment
Daiichi Sankyo Company, Limited recently announced it is making an initial 15 billion yen investment to optimize and enhance its manufacturing capabilities to support its…
Cambridge Epigenetix Licenses Fundamental DNA Methylation IP
Cambridge Epigenetix recently announced it has entered into an exclusive license agreement with Boston Children’s Hospital giving access to leading-edge DNA profiling technologies, which may…
Agios & Aurigene Enter Exclusive License Agreement
Agios Pharmaceuticals, Inc. and Aurigene Discovery Technologies Limited recently announced a global license agreement to research, develop, and commercialize small molecule inhibitors of an undisclosed…
Aptar Pharma Partners With Kali Care to Develop Real-Time Medication Management Technology
Aptar Pharma and Kali Care have announced that they entered into a partnership in order to address the challenge of monitoring adherence in ophthalmic clinical…
Aptar Pharma Partners With Kali Care to Develop Real-Time Medication Management Technology
Aptar Pharma and Kali Care have announced that they entered into a partnership in order to address the challenge of monitoring adherence in ophthalmic clinical…
Teneobio's Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine Release
Teneobio, Inc, a next-generation antibody therapeutics company, recently announced the discovery of a large panel of human anti-CD3 binders with diverse affinities and tune-able T-cell…
Teneobio's Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine Release
Teneobio, Inc, a next-generation antibody therapeutics company, recently announced the discovery of a large panel of human anti-CD3 binders with diverse affinities and tune-able T-cell…
EXECUTIVE INTERVIEW - Oasmia Pharmaceutical: Commercializing Technologies While Pursuing the US Market
Julian Aleksov, Executive Chairman of Oasmia Pharmaceutical, discusses his company’s efforts to enter the US market, its strategy to increase commercial adoption, and why it believes its underlying drug delivery system technology is significant not only within the oncology sector, but the entire pharmaceutical industry.
MilliporeSigma Collaborates with LabCentral to Foster Biotech Startups
MilliporeSigma recently announced the company will sponsor the Startup Program at LabCentral, a biotechnology incubator, in Cambridge, MA. LabCentral is a private, non-profit organization that…
Metrion Biosciences & Venomtech Announce Research Collaboration
Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and Venomtech Limited (Venomtech) a biotechnology company with the UK’s largest venom…
